Abbott Laboratories 2012 Annual Report Download - page 13

Download and view the complete annual report

Please find page 13 of the 2012 Abbott Laboratories annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 68

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68

An Innovative Portfolio of Medical Devices
Abbott’s medical devices group is composed of primarily our vascular,
diabetes care and vision care businesses. Each of these businesses
maintains leadership positions in important segments of the markets
in which they compete.
Our vascular business is active in three franchises: coronary, endovascular
and structural heart. In our coronary franchise, we are expanding our
leadership position in drug-eluting stents with new additions such as Xience
Xpedition, which offers increased deliverability. Absorb, our bioresorbable
vascular scaffold, is a unique technology that acts like a drug-eluting
stent but, unlike a metallic stent, resorbs into the body over time, similar
to dissolvable sutures after a wound heals. Our endovascular franchise,
which includes peripheral catheters and stenting systems, carotid stents
and vessel closure devices, represents a significant opportunity for growth.
We’re applying our expertise in developing best-in-class coronary devices
to the faster growing endovascular market. And, finally, in our structural
heart franchise, we have developed MitraClip, a first-of-its-kind technology
designed to treat mitral regurgitation, which is the leaking of the heart’s mitral
valve. MitraClip has significant long-term potential, given the millions of patients
with significant mitral regurgitation who go untreated today. Both MitraClip
and Absorb are available in a number of international markets and are
investigational devices under U.S. Food and Drug Administration review.
In diabetes care, our focus is to help people with diabetes better manage
this serious metabolic condition by improving the glucose testing experience.
We offer innovative glucose monitoring systems, test strips and software for
both personal and hospital use. Easy to use, highly accurate, and designed
to address specific patient needs, our blood-glucose monitoring systems for
personal use include FreeStyle Lite, FreeStyle Optium and FreeStyle InsuLinx,
which was developed to accommodate the specific needs of insulin users.
Our state-of-the-art software helps users easily recognize glucose trends,
providing meaningful insights to patients and their healthcare professionals.
In the hospital environment, products like Precision Xceed Pro are developed
to meet the challenges of point-of-care glucose testing.
In vision care, Abbott is the world’s leading provider of laser vision correction
(LASIK) technologies and number two in cataracts. We offer eye-care
professionals the industry’s most advanced laser vision technologies.
Today’s Abbott
MitraClip
Structural Heart
11
Abbott 2012 Annual Report